Practice Applications for Immunotherapy in Advanced CSCC: A Clinical Forum℠
Program Overview
In this interactive panel of multidisciplinary experts including a dermatologist and two medical oncologists, discuss the rationale for immunotherapy in CSCC, a brief overview of mechanism of action of immunotherapy and impact on side effects as well as safety and efficacy of approved checkpoint inhibitors, and identifying patients who may benefit from immunotherapy.
This activity is intended for oncology and dermatology clinicians who manage patients with cutaneous squamous cell carcinoma (CSCC).
Educational Objectives
Upon completion of this activity, participants should be better able to:
Delineate the safety and efficacy of immunotherapeutic agents for cutaneous squamous cell carcinoma (CSCC)
Effectively manage immune-mediated adverse reactions associated with the mechanism of action of checkpoint inhibitors
Select therapy for individual patients according to current evidence and guidelines, offering clinical trial enrollment where appropriate
Activity Faculty
Chrysalyne Schmults, MD, MSCE (Chair)
Associate Professor, Dermatology
Harvard Medical School Director, Mohs and Dermatologic Surgery Center Vice Chair, Surgical Oncology for the Department of Dermatology
Brigham and Women’s Faulkner Hospital/Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Paolo Bossi, MD
Associate Professor, Medical Oncology
University of Brescia
Brescia, Italy
Axel Hauschild, MD
Professor, Dermatology Head, Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany
Céleste Lebbe, MD, PhD
Professor, Dermatology Head of the Oncodermatology Center
Dermatology Department
AP-HP Hôpital Saint Louis
Paris Diderot Université
INSERM U976
Paris, France